Drug Trial Radar · NCT03671967
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,084
Planned (sponsor's estimate)
Start
May 1, 2019
Primary completion
Jan 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Rambam Health Care CampusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rabin Medical Center; University of Modena and Reggio Emilia; Tel Aviv Medical Center; Meir Medical Center; Soroka University Medical Center; The Chaim Sheba Medical Center; McGill University Health Centre/Research Institute of the McGill University Health Centre; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Hadassah Medical Organization
- First posted
- Sep 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.
Conditions
- Beta Lactam Resistant Bacterial Infection
- Enterobacteriaceae Infections
- Bacteremia
Interventions
Piperacillin/tazobactamDrug
4.5 grams QID
MeropenemDrug
1 gram TID
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: 30 days from randomization
- Treatment failureTime frame: 7 days from randomization
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health
Calgary, Alberta, Canada · Recruiting
Surrey Memorial Hospital - Fraser Health Authority
Surrey, British Columbia, Canada · Recruiting
Eastern Health
St. John's, Newfoundland and Labrador, Canada · Recruiting
Kingston General Hospital
Kingston, Ontario, Canada · Recruiting
Jewish Genral Hospital
Montreal, Quebec, Canada · Recruiting
Soroka Medical Center
Beersheba, Israel · Recruiting
Hadassah Medical Center
Jerusalem, Israel · Recruiting
Meir Medical Center
Kfar Saba, Israel · Recruiting
Sanz Medical Center-Laniado Hospital
Netanya, Israel · Recruiting
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel · Recruiting
Sheba Medical Center (Tel HaShomer)
Tel Aviv, Israel · Recruiting
Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Rambam Health Care Campus
Haifa, Israel, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.